Safety assessment of menaquinone-7 for use in human nutrition  by Ravishankar, Basavaias et al.
ww.sciencedirect.com
j o u r n a l o f f o o d and d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 9 9e1 0 8Available online at wScienceDirect
journal homepage: www.j fda-onl ine.comOriginal ArticleSafety assessment of menaquinone-7 for use in
human nutritionBasavaias Ravishankar a,5, Yogesh A. Dound b, Dilip S. Mehta b,
Basti Krishana Ashok a,5, Anselm de Souza b, Min-Hsiung Pan c,*,
Chi-Tang Ho d,**, Vladimir Badmaev e, Ashok D.B. Vaidya f
aDepartment of Pharmacology Laboratory, Institute of Postgraduate Teaching and Research,
Gujarat Ayurved University, Jamnagar, India
bViridis Biopharma Private Limited, Mumbai, India
c Institute of Food Science and Technology, National Taiwan University, Taipei 10617, Taiwan
dDepartment of Food Science, Rutgers University, New Brunswick, NJ, USA
e P.L. Thomas & Co., Inc., Morristown, USA
fMedical Research CenterdKasturba Health Society, Mumbai, Indiaa r t i c l e i n f o
Article history:
Received 22 July 2013
Received in revised form
24 March 2014
Accepted 31 March 2014
Available online 6 May 2014
Keywords:
acute toxicity
genotoxicity
menaquinone-7
subacute toxicity
vitamin K* Corresponding author. Institute of Food Sci
** Corresponding author. Department of Food
E-mail addresses: mhpan@ntu.edu.tw (M
5 Presently at SDM Centre for Research in
http://dx.doi.org/10.1016/j.jfda.2014.03.001
1021-9498/Copyright ª 2014, Food and Drug Ada b s t r a c t
Vitamin K occurs widely in foods and has been shown to have a beneficial effect on the
cardiovascular system, as well as anticancer, anti-inflammatory, and antiosteoporosis
properties. A previous study indicates that long-chain menaquinone-7 may be more
bioavailable than vitamin K and short-chain menaquinones. In the present study, acute,
subacute toxicity and genotoxicity assays were carried out to evaluate the safety of oral
menaquinone-7 in albino Wistar rats. Oral administration of menaquinone-7, at a con-
centration of 2000 mg/kg, did not cause toxic symptoms in either male or female rats. A
subacute toxicity study also proved the safety and tolerance of prolonged treatment (for 90
days) with menaquinone-7 in rats, as evidenced by biochemical, hematological, and urine
parameters as well as by histopathological analysis. Genotoxicity and mutagenicity studies
were performed by comet, micronucleus, and Ames tests on Salmonella typhimurium
strains, which showed cellular safety and nonmutagenicity of menaquinone-7. The results
indicate the safety of menaquinone-7 for human consumption.
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It was discovered over 80 years ago that food-derived compo-
nents are essential factors in blood coagulation. In 1929,
experimental studies at the University of Copenhagen using
chicks fed a diet extremely low in fat revealed that low-fat-diet
birds developed a hemorrhagic condition and their blood
coagulation time was slower than that in the control group [1].
Further investigations showed that the deficiency of a fat-
soluble vitamin, vitamin K, was responsible for the hemor-
rhagic tendency. Vitamin K occurs in two biologically active
forms: phylloquinone (vitaminK1) andmenaquinones (vitamin
K2). Vitamin K1 is produced by green and leafy vegetables, and
algae, whereas vitamin K2 is predominantly of microbial origin
[2,3]. The major form of dietary vitamin K is considered to be
K1, accounting forw90% of total vitamin K intake [3]. Vitamin
K2 is found in animal products, meat, dairy, eggs, and fer-
mented foods such as cheese, yoghurt, and the traditional
Japanese food natto (Bacillus natto fermented soya beans);
vitamin K2 is also synthesized by intestinal microflora [4].
In addition to its role in the synthesis of hepatic blood-
coagulation proteins, vitamin K has been found to play a
role in bone health, cardiovascular health, prevention of
cancer, suppression of inflammation, prevention of brain
oxidative damage, sphingolipid synthesis, and osteoporosis
[5e9]. Epidemiological studies from Japan and Europe suggest
an association between poor vitamin K2 (but not vitamin K1)
intake and increased postmenopausal bone loss, arterial
calcification (notably in diabetes), end-stage renal disease,
and cardiovascular disease during normal aging, as well as an
increased risk of bone fracture [10,11]. Supplementation with
vitamin K2 may prevent age-related bone loss and improve
bone strength, arterial elasticity, and cardiovascular health
[12e15]. Available information indicates that current intake of
vitamin K, particularly K2, may not be sufficient for the
maintenance of bone health and cardiovascular health [16,17].
Compared to phylloquinone, menaquinones, especially
long-chainmenaquinone-7,maybebeneficial forboneandsoft
tissue, specifically for protein carboxylation and production.
This is probably because menaquinone-7 is better absorbed
and is more bioavailable than vitamin K1 or short-chain
menaquinones such as menaquinone-4. Because there is a
paucity of studies on the toxicity of menaquinones, especially
long-chain menaquinones, we present in this paper a system-
atic toxicity and safety study of oral vitamin K2e7 in rodents.2. Materials and methods
2.1. Chemicals
Vitamin K2e7 (MenaquinGold) was provided by Viridis Bio-
pharma Pvt. Ltd. (Mumbai, India). All other chemicals used
were commercially available in the purest form.
2.2. Animals
Male and female 7e8-week-old albino Wistar rats were ob-
tained from the experimental animal facility at GujaratAyurved University, Jamnagar, India. Animals were housed in
polypropylene cages under a controlled atmosphere (25  1C
at 60e70% relative humidity) with a 12-hour lighte12-hour
dark cycle [18]. All animals were fed with Amrut brand rat
pellet feed supplied by Pranav Agro Ltd. (Pune, India) and tap
water ad libitum. Following at least 1 week of acclimatization,
the rats were divided randomly into seven groups of eight
animals each for experiments, as discussed below.
Menaquinone-7 compound was suspended in a propylene
glycol vehicle. Test formulations were administered to the
animals through oral gavage. All procedures were in accor-
dance with the guiding principles established by the Animal
Care Committee of our University.
2.3. Oral acute toxicity
The toxicity study was conducted according to the modified the
Organisation for Economic Co-operation and Development
(OECD) protocol as practiced by the Institute for Post Graduate
Teaching and Research in Ayurveda and was cleared by the
Institutional Review Board (IRB) (IAEC-04/09-10/Proj-02) of
Gujarat Ayurveda University, Udupi, India. Healthy, 10e12-
week-old Albino Wistar rats (n ¼ 40) of average weight
(150e210 g) were randomly divided into five groups, with four
male and four female rats in each group, and kept in separate
cages.Theanimalsweresuppliedad libitumwithwaterandpellet
feed throughout the study, and subjected to overnight fasting
prior to dosing with menaquinone-7 or placebo. The control
group received propylene glycol vehicle, and each treated group
receivedmenaquinone-7,atdosesof0.5mg/kg,1.0mg/kg, 10mg/
kg,or20mg/kg,oncedailyfor14days.LD50valuewasdetermined
by administrationof a single dose of 2000mg/kgmenaquinone-7
for 14 days. The animals were monitored for general behavior,
toxic signs and symptoms, ormortality during the experimental
period.Attheendofthestudy, theanimalsweresacrificedbyCO2
asphyxiation and examined for gross changes in vital organs.
2.4. Ninety-day subacute oral toxicity in rats
2.4.1. Animal treatment
The protocol employed was a modified version of the OECD
guideline 408. Ten animals per group, five male and five fe-
male Wistar Albino rats, were used instead of 10 male and 10
female rats as in the original OECD protocol. The animals were
oral treated with 0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg
menaquinone-7 once daily for a period of 90 days. Animals of
the control group received propylene glycol as the vehicle.
Menaquinone-7 solution was prepared fresh every day and
administered at a constant volume of 1 mL/100 g body weight
between 8 AM and 9 AM. Behavior, mortality, and changes in
body weight and food consumption were recorded. Upon
completion of 90-day subchronic protocol sacrifice, autopsy of
animals and histopathology of selected organs were per-
formed. The number of experimental animals per group was
approved by the Ethics Committee of the Institutional Review
Board of Gujarat Ayurveda University (IAEC-04/09-10/Proj-02).
2.4.2. Biochemical and hematological analysis
Evaluation of blood biochemistry was carried out in all the
animals on Day 15, Day 45, and Day 91 at the time of sacrifice.
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collected by supraorbital puncture, with the help of micro-
capillary tubes under mild ether anesthesia. Blood sugar,
serum urea, creatinine, uric acid, total cholesterol, tri-
glycerides, total protein, albumin-to-globulin ratio (A/G ratio),
liver enzymes serum glutamic oxaloacetic transaminase
(SGOT) and serum glutamic pyruvic transaminase (SGPT),
alkaline phosphatase activity, and serum calcium levels were
estimated with a clinical analyzer (ERBA CHEM-5; GMI, Inc.,
Ramsey, MN, USA).
Hematological parameters were measured using an auto-
cell counter (MS-9 veterinary hematology cell counter; Melet
Schloesing, France), including total white blood cell (WBC)
count, total lymphocyte count, total monocyte count, total
granulocyte count, lymphocyte percentage, monocyte per-
centage, granulocyte percentage, red blood cell (RBC) count,
hemoglobin, hematocrit, mean corpuscular volume, mean
corpuscular hemoglobin, mean corpuscular hemoglobin con-
centration, RBC distribution width, and clotting time.
2.4.3. Urine analysis
Qualitative urine analysis of the experimental animals was
carried out using AMES multiple kits on Day 15 and Day 45,
and at the time of sacrifice on Day 91. Urine was collected in
dry-ice-cooled beakers. After collection, the urine samples
were thawed, vigorously mixed, and analyzed for specific
gravity and pH.
2.4.4. Histopathology analysis
Male and female rats were sacrificed on Day 91 and autopsied.
The abdomen was opened through midline incision, followed
by dissection of the selected organs that were then cleaned
and weighed. The organs were placed in containers filled with
10% formalin for tissue preservation, and histopathology of
the brain, pituitary, thymus, lymph node, heart, lungs, spleen,
seminal vesicles, uterus, skin, trachea, liver, stomach,
jejunum, kidney, testis, prostate, and ovary was determined.
2.4.5. Statistical analysis
The Student t test for paired datawas employed for comparing
differences within the group and one-way analysis of variance
(one-wayANOVA)was employedwith Dunnet’smultiple t test
as a post hoc test for comparison of observed changes among
different groups. For this purpose, Sigmastat software (version
3.1) was used.
2.5. Genotoxicity study
Albino Wistar rats (n ¼ 60; 30 males and 30 females), average
weight 200e300 g, were randomly divided into six groups,
each group containing five male and five female rats, and
placed in separate cages. All animals had ad libitum tap water
and pellet feed. The animals received menaquinone-7 at a
dose of 0.1 mg/kg or 1.0 mg/kg once daily for 28 days. Two
groups were maintained as controls for comparative assess-
ment of genotoxicity through comet assay and micronucleus
test. Animals in control groups received cyclophosphamide at
a dose of 40 mg/kg body weight intraperitoneally on Day 29.
Colchicine was administered on Day 30 to three groups and
one control group, and 0.1mg/kg or 1.0 mg/kgmenaquinone-7to the other groups. Two hours after colchicine administra-
tion, blood was collected from all animals for genotoxicity
assessment using comet assay. The animals were sacrificed
by cervical dislocation and evaluated for gross pathology of
internal organs, and femur bones were collected for chromo-
somal aberration and micronucleus tests.
2.6. Ames test
Mutagenic effect was examined by Salmonella typhimurium
reverse mutation assay at selected histidine loci in five tester
strains, viz. TA1535, TA97a, TA98, T100, and TA102, in the
presence and absence of a metabolic activation system (S9).
The tester strains were exposed to menaquinone-7 in tripli-
cate cultures at doses of 0.02 mg, 0.06 mg, 0.2 mg, 0.6 mg, or
2 mg. The plate incorporation method was followed for the
test.
Suspensions of bacterial cells were exposed to the test
article in the presence and absence of an exogenousmetabolic
activation system. These suspensions were mixed with an
overlay agar and plated immediately onto minimal medium.
After a 48e72-hours incubation period, revertant colonies on
vehicle control plates were checked for sterility. The plates
were observed for uniform lawn of auxotrophs and the col-
onies for histidine revertants as prototrophs. Histidine rever-
tant colonies per plate were counted, and themean number of
colonies at each test point was calculated.
2.7. Statistical analysis
Results were expressed as the means  standard deviation.
Differences between groups were evaluated using one-way
analysis of variance, followed by Dunett’s t test. All statisti-
cal analyses were performed using the statistical software
SPSS 11.0 (SPSS Ltd.,Working, Surrey, UK). A p value<0.05was
considered statistically significant [19].3. Results
3.1. Acute toxicity study
No physical or behavioral changes and no mortality were
recorded for all experimental rats after 14 days’ gavage
administration of various concentrations of menaquinone-7.
A gradual physiological gain in body weight occurred in both
male and female animals of all experimental groups,
including the control group. No statistically significant dif-
ference in body weight gain was observed among the test
groups and between test groups and the control group. The
test compound did not produce any mortality or clinical signs
of toxicity at the highest treatment dose of menaquinone-7
(20 mg/kg). The test compound did not produce any observ-
able toxic effects except formild irritability in two animals out
of eight (25%) in the dose group of 1 mg/kg of menaquinone-7.
Water and food consumptions were not affected by adminis-
tration of the formula in all dosing groups and the control
group. The results of 14-day oral administration of
menaquinone-7 in an acute toxicity study showed no adverse
effects of the test compound on either sex of Wistar rats. For
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with no significant change in body weight, and no symptoms
of distress or toxic effects. The study showed that the LD50
value of the formula is more than 2000 mg/kg body weight.
3.2. Ninety-day subacute oral toxicity
3.2.1. General observation
All treatment and placebo receiving groups exhibited a normal
bodyweight gain pattern. Inmale rats of the control group, the
average bodyweight gain from the baseline to Day 90was 66 g,
with 82 g, 87 g, and 62 g gains using menaquinone-7 at con-
centrations of 0.1 mg/kg, 0.5 mg/kg, and 1 mg/kg, respectively.
In female rats, the average body weight gain by Day 90 was
30 g in the control group, and 35 g, 33 g, and 48 g in the
menaquinone-7 group at concentrations 0.1mg/kg, 0.5 mg/kg,
and 1 mg/kg, respectively. These weight gains are not statis-
tically significant. Moreover, administration of 0.1 mg/kg,
0.5 mg/kg, and 1 mg/kg menaqinone-7 to male rats did not
statistically affect the average weight of the liver, thymus,
kidney, spleen, testis, seminal vesicles, prostate, and uterus to
a significant extent in comparison to the sham-fed control
group. Female rats receiving menaquinone-7 at a dose of
0.5 mg/kg showed a statistically significant (p < 0.05) decrease
in heart weight in comparison to the control group. The
average heart weight was 0.333  0.009 g in the control group
and 0.292  0.010 g in the menaquinone-7 group (0.5 mg/kg).
3.2.2. Effect of menaquinone-7 on biochemical parameters in
rats
Male and female rats administered menaquinone-7 at con-
centrations of 0.1 mg/kg, 0.5 mg/kg, and 1 mg/kg did not show
a statistically significant effect on the blood levels of liver
enzymes, including SGPT, SGOT, and alkaline phosphatase
(ALP); serum glucose; total protein; creatinine; and blood urea
levels in comparison to the control group. In the male group
receivingmenaquinone-7 at a dose of 0.1 mg/kg, a statistically
significant decrease in uric acid level was observed on Day
45. A comparison of baseline values (3.24  0.22 mg/dL)
compared to baseline value of 3.82  0.31 (mg/dL) (p < 0.05),
but did not show a statistically significant difference from the
corresponding values in the control group (3.30  0.31 mg/dL)Table 1 e Effect of the 90-day subacute toxicity of menaquinon
Uric acid (mg/dL) M
Control 0.1 m
Male rats
Day 0 3.50  0.02 3.96 
Day 45 3.30  0.31 3.24 
Day 90 3.40  0.14 0.42 
Female rats
Day 0 3.54  0.16 3.30 
Day 45 3.64  0.12 3.16 
Day 90 3.76  0.14 3.74 
*p < 0.05 with reference to initial values in the concerned group (paired t
**p < 0.01 with reference to initial values in the concerned group (paired
#p < 0.05 with reference to values in the control group (paired t test).
##p < 0.01 with reference to values in the control group (paired t test).(Table 1). In the 0.5 mg/kg and 1 mg/kg menaquinone-7
groups, a statistically significant (p < 0.05) increase was
observed in the uric acid level when compared to the baseline
levels (from2.70 0.22mg/dL to 3.82 0.24mg/dL onDay 90 in
the 0.5 mg/kg group, and from 3.82  00.31 to 4.64  0.20 on
Day 45 and from 3.82  0.31 to 4.02  0.14 on Day 90 in the
1 mg/kg group). The increase of uric acid level observed in the
1 mg/kg menaquinone-7 male group on Day 45 was also sta-
tistically significantly higher (p < 0.05) than that in control
male rats. There was no change in the uric acid levels in the
female rats as compared to the baseline and control values
(Table 1).
The A/G ratio did not change statistically significantly in
0.5mg/kg and 1mg/kgmale rat groups onDay 45 andDay 90 in
comparison to the respective baseline values as well as con-
trol group values. However, in the 0.1 mg/kg menaquinone-7
group, a statistically significant decrease in the A/G ratio
was observed on Day 45 as compared to the baseline (from
1.04  0.06 to 0.59  0.07; p < 0.01) and the control values
(0.59  0.07 in the 0.1 mg/kg menaquinone-7 group compared
to 1.16  0.08 in the control group). In female rats, the control
group showed a statistically significant (p < 0.05) increase in
the A/G ratio on Day 90 in comparison to the baseline values
(1.29  0.01 on Day 90 compared to the baseline value of
1.06  0.07). In addition, on Day 90, a statistically significant
increase in the A/G ratio was observed in the 0.5 mg/kg group
in comparison to the baseline values (1.33  0.05 compared to
the baseline value of 1.06  0.03) and in the 0.1 mg/kg group in
comparison to the control group value (1.45  0.04 compared
to 1.29  0.01 in the control group; p < 0.01; Table 2). In female
rats treated with menaquinone-7 at a dose of 0.1 mg/kg, a
statistically significant decrease in the A/G ratio was observed
on Day 45 in comparison to the baseline values (from
1.30  0.33 to 0.69  0.02; p < 0.01).
The effects of menaquinone-7 administration on serum
albumin and globulin levels are shown in Table 2. In female
rats treated with 0.1 mg/kg menaquinone-7, serum albumin
level on Day 45 was statistically significantly lower in com-
parison to the baseline values (p < 0.01), with no statistically
significant differences between control group and menaqui-
none-7-receiving groups (0.5 mg/kg and 1 mg/kg). The serum
globulin level in male rats of the control and 0.5 mg/kge-7 on uric acid (mg/dL) level in rats.
enaquinone-7 concentrations
g/kg 0.5 mg/kg 1 mg/kg
0.16 2.70  0.22 3.82  0.31
0.22* 3.78  0.29 4.64  0.02*,##
0.21 3.82  0.24** 4.02  0.14#
0.17 2.96  0.75 3.54  0.29
0.24 3.88  0.57 3.66  0.44
0.20 4.14  0.10 3.68  0.17
test).
t test).
Table 2 e Effect of 90-day subacute toxicity of menaquinone-7 on serum albumin, globulin levels, and A/G ratio in rats.
Parameters Menaquinone-7 concentrations
Control 0.1 mg/kg 0.5 mg/kg 1 mg/kg
Serum albumin (mg/dL)
Male rats
Day 0 4.56  0.19 4.84  0.14 4.46  0.09 4.36  0.18
Day 45 4.28  0.22 3.04  0.30** 4.53  0.12 4.50  0.22
Day 90 4.66  0.20 4.52  0.37 4.32  0.14 4.72  0.15
Female rats
Day 0 4.72  0.09 4.58  0.09 4.60  0.12 4.58  0.10
Day 45 4.34  0.14** 3.10  0.11***,## 4.28  0.26 4.64  0.17
Day 90 4.46  0.16 4.95  0.09 4.78  0.13 4.66  0.17
Serum globulin (mg/dL)
Male rats
Day 0 4.80  0.11 4.68  0.18 4.54  0.17 4.40  0.35
Day 45 3.62  0.18** 5.18  0.09*,## 3.60  0.16* 4.00  0.18
Day 90 3.84  0.14* 3.54  0.21* 3.34  0.13** 3.70  0.07
Female rats
Day 0 4.48  0.21 3.64  0.34 4.32  0.08 4.58  0.15
Day 45 3.62  0.24 4.42  0.10 3.84  0.16* 4.02  0.15*
Day 90 3.50  0.24 3.34  0.12 3.58  0.07** 3.58  0.13**
A/G ratio
Male rats
Day 0 0.95  0.04 1.04  0.06 1.00  0.06 1.01  0.09
Day 45 1.16  0.08 0.59  0.07** 1.26  0.07 1.13  0.09
Day 90 1.22  0.08 1.30  0.17 1.30  0.07 1.27  0.03
Female rats
Day 0 1.06  0.07 1.30  0.32 1.06  0.03 1.00  0.04
Day 45 1.21  0.08 0.69  0.02## 1.11  0.55 1.16  0.08
Day 90 1.29  0.01* 1.45  0.04## 1.33  0.05* 1.31  0.08
*p < 0.05 (paired t test) with reference to initial values in the concerned group.
**p < 0.01 (paired t test) with reference to initial values in the concerned group.
***p < 0.001 (paired t test) with reference to initial values in the concerned group.
##p < 0.01 with reference to values in the control group (paired t test).
A/G ratio ¼ albumin to globulin ratio.
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cantly decreased on Day 45 and Day 90 in comparison to the
respective baseline values (p < 0.01). Male rats who received
menaquinone-7 at a dose of 0.1 mg/kg demonstrated a sta-
tistically significant increase of globulin levels on Day 45
(p < 0.01) but a statistically significant decrease in globulin
values on Day 90 (p < 0.01), as compared to the baseline and
control group. No statistically significant changes in globulin
levels were found in the 1 mg/kg menaquinone-7 group, in
either male or female rats, as compared to the respective
baseline and control values. A statistically significant increase
in globulin levels in comparison to the control group was
observed on Day 45 in female rats at 0.1 mg/kg dose of
menaquinone-7 (p < 0.01). In the 0.5 mg/kg and 1 mg/kg dose
groups, female rats showed a statistically significant decrease
in globulin levels on Day 45 and Day 90 in comparison to the
respective baseline values (p < 0.001 and p < 0.05). However,
no statistically significant difference was observed in globulin
levels between the control group and menaquinone-7-
administered group (Table 2).
The results of total cholesterol analysis of male rats in
both the control group and menaquinone-7-administered
group displayed a statistically significant decrease in the
total serum cholesterol on Day 45 in comparison to the
baseline levels (p< 0.05 in the control group and p< 0.01 in themenaquinone-7 group; Table 3). The blood cholesterol levels
in menaquinone-7-receiving groups (all dose groups) did not
differ significantly from those of the control group, in both
male and female rats, on Day 90. Female rats treated with
0.5 mg/kg menaquinone-7 showed a statistically significant
decrease (p < 0.05) in blood cholesterol on Day 45 in com-
parison to the baseline values. In addition, the level of blood
cholesterol in the 1 mg/kg menaquinone-7 group on Day 45
was significantly lower than that in the control group
(p < 0.05). High-density lipoprotein (HDL)-cholesterol levels in
male rats at all time points were not statistically significantly
changed from the baseline and in comparison to the control
group (Table 3). In female rats, there was no statistically sig-
nificant change in HDL-cholesterol levels from the baseline.
However, in comparison to the control group, HDL-cholesterol
levels in all dose groups were found to be statistically signif-
icantly lower on Day 90 (p < 0.05). On Day 45, serum triglyc-
eride levels in male rats of the control and 0.1 mg/kg
menaquinone-7 groups were found to be statistically signifi-
cantly lower than the respective baseline levels (p < 0.05;
Table 3). Triglyceride levels on Day 45 in male rats adminis-
tered the 1 mg/kg dose were statistically significantly
increased in comparison to the baseline (p< 0.05), but showed
no statistically significant difference on Day 90 from the
baseline and control levels.
Table 3 e Effect of 90-day subacute toxicity of menaquinone-7 on serum total cholesterol, HDL-cholesterol, and triglyceride
levels in rats.
Parameters Menaquinone-7 concentrations
Control 0.1 mg/kg 0.5 mg/kg 1 mg/kg
Total cholesterol (mg/dL)
Male rats
Day 0 180.82  5.62 194.72  0.30 180.20  4.12 186.00  5.10
Day 45 164.08  4.12* 176.44  5.22** 164.84  9.49* 157.80  7.20
Day 90 168.72  18.99 185.72  2.80 181.10  3.45 183.24  3.77
Female rats
Day 0 195.78  1.43 173.40  2.29 186.20  3.60 180.20  3.51
Day 45 185.94  5.05 171.40  3.54 161.48  5.99* 161.66  5.11#
Day 90 188.52  2.74 181.96  4.64 183.20  2.31 184.80  2.03
HDL-cholesterol (mg/dL)
Male rats
Day 0 34.94  1.86 36.02  1.32 35.48  1.63 33.00  3.10
Day 45 30.94  1.15 35.72  1.85 34.36  2.08 33.54  1.41
Day 90 37.14  2.01 33.24  0.65 32.54  1.01 31.10  1.12
Female rats
Day 0 35.66  1.22 30.40  1.03 35.40  1.86 35.60  0.98
Day 45 35.92  1.60 32.82  1.89 37.16  0.53 37.04  1.04
Day 90 39.10  0.57 31.98  1.54 32.88  0.76 34.80  0.50#
Triglyceride (mg/dL)
Male rats
Day 0 107.20  4.85 105.12  4.87 112.60  13.65 94.20  8.48
Day 45 71.64  5.83* 92.18  3.39* 107.20  2.52# 100.90  2.74#
Day 90 110.00  5.00 108.70  3.85 116.60  7.01 122.00  16.66
Female rats
Day 0 100.46  4.14 93.00  3.39 104.80  5.27 118.20  15.04
Day 45 111.40  4.93 94.04  5.76 111.30  3.53 97.80  2.08
Day 90 129.20  5.71* 110.50  4.06 113.70  4.10 118.54  4.49
*p < 0.05 with reference to initial values in the concerned group (paired t test).
**p < 0.01 with reference to initial values in the concerned group (paired t test).
#p < 0.05 with reference to values in the control group (paired t test).
HDL ¼ high-density lipoprotein.
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in rats
A statistically significant decrease in total WBC count was
observed onDay 90 in bothmale and female rats of the control
group in comparison to the baseline counts (Table 4). Rats
receiving menaquinone-7 at a dose of 0.1 mg/kg showed a
significantly decreasedWBC count on Day 45 in comparison to
the baseline count (p< 0.01). The percentage of lymphocytes in
the control male and female rats was not statistically signifi-
cantly different on Day 45 and Day 90 in comparison to the
baselineandmenaquinone-7-receivinggroups.Menaquinone-
7 treatment (0.1 mg/kg) caused a statistically significant
decrease of lymphocytes in male rats (p < 0.05) on Day 90. A
statistically significant increase in lymphocytes was seen in
female rats receiving 1 mg/kg of menaquinone-7 in compari-
son to the baseline on Day 45 (p < 0.05). The percent of gran-
ulocytes did not change statistically significantly in male rats
of the 0.5mg/kg and 1mg/kg dose groups onDay 45 andDay 90
in comparison to the baseline values. However, male rats
treated with menaquinone-7 at a dose of 0.1 mg/kg showed a
significant increase of granulocytes in comparison to the
baseline on Day 45 (p < 0.05).
Table 5 shows the RBC count and hematocrit values after
menaquinone-7 treatment. RBC count and hematocrit valuesin both male and female rats in the control group were
significantly decreased on Day 90 in comparison to the base-
line. Male rats treated with 0.1 mg/kg menaquinone-7
demonstrated a significant increase in RBC count and he-
matocrit values on Day 45 in comparison to the baseline. A
significant increase of RBC count on Day 45 was also observed
in both male and female rats treated with 1 mg/kg
menaquinone-7 in comparison to the baseline (p < 0.01). No
statistically significant change in RBC and hematocrit values
was observed between the control and three dosing male and
female groups at any testing time point.
Hemoglobin levels were statistically significantly
decreased on Day 45 and Day 90 in male control rats in com-
parison to the baseline (p < 0.01). Female rats in the control
group showed a significant decrease of hemoglobin levels on
Day 90 (p < 0.05). A significant increase of hemoglobin levels
was noted on Day 45 in male rats treated with 0.1 mg/kg
menaquinone-7 (p < 0.05), whereas a decrease was seen at a
dose of 1mg/kg (p< 0.05), in comparison to the baseline. There
was no statistically significant change in hemoglobin levels
between the control and three dosingmale and female groups
at any testing time point. Additionally, there was no statisti-
cally significant difference in the mean corpuscular hemo-
globin, mean corpuscular hemoglobin concentration, mean
Table 4 e Effect of 90-day subacute toxicity of menaquinone-7 on hematological parameters in rats.
Parameters Menaquinone-7 concentrations
Control 0.1 mg/kg 0.5 mg/kg 1 mg/kg
Total WBC count (103/mL)
Male rats
Day 0 8.44  1.30 6.32  0.71 7.32  0.10 8.72  1.06
Day 45 6.50  0.14 5.06  0.57 5.14  0.54 7.48  0.90
Day 90 4.28  0.99* 4.74  0.99 7.76  2.47 6.32  2.23
Female rats
Day 0 8.52  1.16 9.08  1.37 7.88  1.58 7.80  1.01
Day 45 5.76  0.29 5.26  0.22** 8.48  1.80 8.24  0.31
Day 90 3.14  0.33*** 4.30  0.88 4.08  0.58 4.50  1.14
Lymphocytes (%)
Male rats
Day 0 67.22  5.75 50.48  3.73 59.88  7.07 49.26  6.08
Day 45 64.34  3.89 52.92  0.30 66.46  2.06 55.58  9.92
Day 90 59.40  10.98 23.34  7.89* 55.08  2.43 47.52  7.11
Female rats
Day 0 50.52  5.78 56.16  9.64 61.46  10.29 50.96  4.31
Day 45 66.14  3.29 56.58  2.99 70.98  4.08 71.88  1.07*
Day 90 52.96  10.63 36.93  14.44 56.98  3.53 46.16  5.49
Granulocyte (%)
Male rats
Day 0 13.94  6.54 13.90  7.24 17.80  8.97 29.92  7.24
Day 45 24.66  5.09 36.68  0.54* 23.70  2.02 33.04  9.93
Day 90 24.58  10.68 59.28  11.97 26.28  4.28 32.48  8.93
Female rats
Day 0 29.10  9.74 29.14  9.98 21.48  9.75 27.88  8.93
Day 45 21.60  5.26 35.62  4.26 25.98  2.89 16.78  1.39
Day 90 32.54  11.55 41.75  18.07 26.26  5.02 35.94  7.21
*p < 0.05 with reference to initial values in the concerned group (paired t test).
**p < 0.01 with reference to initial values in the concerned group (paired t test).
***p < 0.001 with reference to initial values in the concerned group (paired t test).
WBC ¼ white blood cell.
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clotting time between the control and three dosing male and
female groups at any testing time point.
3.2.4. Effect of menaquinone-7 on urine parameters in rats
The analysis of urine on Day 45 and Day 90 did not show
statistically significant changes in specific gravity and pH in
either sex of all the treatment groups in comparison to the
baseline and control group. In the 0.5 mg/kg and 1 mg/kg test
drug-administered groups (in females), a significant increase
in specific gravity of urine was observed on Day 45 in com-
parison to initial values. However, no such increase could be
observed on Day 90. Change in pH at the dose level of
1000 mg/kg was significant in comparison to the control group
on Day 45.
3.2.5. Histopathology evaluation
No remarkable histopathological changes were observed in
the organs of the control animals and animals treated with
menaquinone-7 (either sex), including the forebrain,
midbrain, hindbrain, cerebellum, pituitary gland, trachea,
lung, spleen, thymus, lymph node, heart, liver, kidney,
stomach, intestine (jejunum), testis, seminal vesicle, ventral
prostate, skin, and bone marrow. However, an increase in the
size of the organ and proliferation of epithelium in uterine
were found in one to two rats in menaquinone-7-treatedgroups at all concentrations, and the remaining rats exhibi-
ted normal cytoarchitecture.
3.3. Genotoxicity testing
The administered menaquinone-7 and placebo did not cause
any symptoms of toxicity, and response of all animals to
handling was normal at testing intervals. There were no gross
pathological findings in the body organs of any experimental
animal. Potential genotoxic effects were examined using
chromosomal aberration, and micronucleus and comet assay
tests. The mean frequency of chromosomal aberrations and
mean number of micronuclei did not differ statistically
significantly between the groups receiving 10 times the rec-
ommended dose of menaquinone-7 (1 mg/kg for 15 consecu-
tive days) as compared to the group that had not received
menaquinone-7 supplementation. The olive tail movement/
cell in the comet assay also revealed no qualitative or quan-
titative DNA damage in the cells of the animals supplemented
with menaquinone-7 as compared to control animals.
3.4. Mutagenicity
Menaquinone-7 was found to be nonmutagenic for tested
S. typhimurium strains TA 1535, TA97a, TA98, TA100, and
TA102. In Ames test, the same frequencies of histamine
Table 5 e Effect of 90-day subacute toxicity of menaquinone-7 on RBC count, hemoglobin content, and hematocrit in rats.
Parameters Menaquinone-7 concentrations
Control 0.1 mg/kg 0.5 mg/kg 1 mg/kg
RBC count (106/mL)
Male rats
Day 0 12.38  0.46 9.80  0.65 8.75  0.63 9.53  0.99
Day 45 13.16  0.77 13.22  0.22* 10.27  1.55 10.07  1.50
Day 90 9.46  0.62* 13.25  1.91 9.56  0.73 13.57  1.46
Female rats
Day 0 9.78  0.21 7.79  0.56 9.51  1.16 8.17  1.40
Day 45 10.82  0.08 9.88  1.61 8.96  0.04 11.92  2.10**
Day 90 8.74  0.37** 11.41  1.90 9.94  0.58 11.43  1.42
Hemoglobin (g/dL)
Male rats
Day 0 23.04  0.17 19.12  1.20 17.76  0.93 19.94  1.54
Day 45 21.18  0.37** 21.58  0.74* 17.30  1.91 15.98  2.38*
Day 90 15.60  0.33*** 21.20  2.10 18.04  1.37 21.96  1.12
Female rats
Day 0 18.30  0.74 16.20  1.01 18.60  1.96 16.30  2.36
Day 45 17.86  1.05 16.70  2.08 16.06  0.73 18.46  1.95
Day 90 15.18  0.23* 18.62  1.92 18.22  1.11 20.08  1.61
Hematocrit (%)
Male rats
Day 0 69.96  3.05 59.54  4.48 51.84  4.13 56.30  5.93
Day 45 72.20  3.39 72.18  1.27* 58.28  8.34 60.22  7.51
Day 90 54.35  3.04* 72.98  9.23 57.96  4.31 74.00  4.54
Female rats
Day 0 53.30  0.99 46.54  2.46 54.72  5.91 48.02  7.92
Day 45 60.04  3.70 55.92  8.34 52.54  2.20 67.88  10.34**
Day 90 50.32  1.67* 63.18  9.08 59.86  3.96 70.20  8.84
*p < 0.05 with reference to initial values in the concerned group (paired t test).
**p < 0.01 with reference to initial values in the concerned group (paired t test).
***p < 0.001 with reference to initial values in the concerned group (paired t test).
RBC ¼ red blood cell.
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menaquinone-7, in tester strains with or without the presence
of a metabolic activation system. Bacterial growth pattern in
the presence of metabolic activation was comparable to that
observed in the vehicle control groups. The incorporation of
menaquinone-7 did not produce any change in microbial
growth patterns, with the number of revertant colonies indi-
cating the tested preparation as nonmutagenic.4. Discussion
In recent years, vitamin K, especially vitamin K2, was found to
have several important physiological functions in addition to
its traditional role in the formation of coagulation factors in
the liver. Data on the safety profile of phylloquinone, vitamin
K1, menatetrenone, and menaquinone-4 are available, but
there are no safety data on menaquinone-7 that is commonly
used in nutritional supplements. Epidemiological data point
to the inadequate intake of menaquinone-7 leading to many
chronic diseases, including coronary heart disease, cancer,
and osteoporosis [5,20]. The length of the side chain in
menaquinones is considered to play an additional role in their
bioavailability. Menaquinones with medium-length side
chains (e.g., MK-7) are better absorbed as compared to those
with short (MK-4) or long (e.g., MK-8 and MK-9) side chains
[21e23]. The different pharmacokinetic properties of MK-7may result in different biological properties, distinct from
other menaquinones. In view of the growing use of MK-7 in
nutritional and food supplements, it is important to test MK-7
in systematic toxicity studies.
The mean intake of total vitamin K in European countries
and USA is estimated to be 60e250 mg/day in adults (Expert
Group on Vitamins and Minerals). In Japan, a traditional
preparation of fermented beans, a rich source of vitamin
MK2e7 known as natto, is sold in a size that usually contains
40e100 g of fermented beans, preferably served at breakfast. A
typical serving pack of natto may contain approximately
350 mg menaquinone-7. We have, therefore, assumed that the
dietary intake of menaquinone-7 may vary from 60 mg/day to
350 mg/day. This amount is equivalent to 5.4e31.5 mg of MK2-7
per kg per day in rats. The concentrations used in our 90-day
subchronic toxicity study (0.1 mg/kg/day, 0.5 mg/kg/day, and
1 mg/kg/day) are approximately 3e200 times higher than
those calculated from the estimated dietary intake in humans.
The outcome of daily oral administration ofmenaquinone-
7 at three concentrations (0.1 mg/kg, 0.5 mg/kg, and 1 mg/kg)
for 90 days to albino Wistar rats of both sexes was evaluated
by assessing changes in behavior, body weight, blood
biochemistry and morphology, urine analysis, and gross and
histopathology of selected organs. Change in the animal body
weight patterns during the course of the 90-day study is a
sensitive indicator of the overall toxicity potential of a test
compound. Any drug that produces significant toxicity to the
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with the nutrient absorption and/or availability is likely to
cause a decrease in the animal body weight. In the 90-day
regimen with menaquinone-7, Wistar albino rats (of both
sexes) showed a nonsignificant body weight gain in compar-
ison to the control rats. This finding indicates that subchronic
administration of menaquinone-7 in doses of up to 200 times
higher than that calculated from daily human dose does not
produce body organ involution and/or does not interfere
with themetabolic utilization of food-derived nutrients. There
was a statistically significant increase in the average liver
weight in the experimental group of male rats receiving
menaquinone-7 at a concentration of 0.1 mg/kg. Female rats
orally treated with menaquinone-7 at doses of 0.5 mg/kg and
1 mg/kg showed a significantly decreased liver weight. More-
over, a statistically significant decrease in the average heart
weight was observed in female animals receiving 0.5 mg/kg of
menaquinone-7. These findings describe statistically signifi-
cant changes in body organ weight that were not dose
dependent and occurred in one sex, and not both sexes, of
animals with normal gross and histopathology of the body
organs.
The following factors were taken into consideration while
evaluating biochemical and hematological parameters in the
toxicological study of menaquinone-7. Each study parameter
was measured three times at the baseline on Day 45 and Day
90. It was further evaluated whether the statistically signifi-
cant changes occurred in a dose-dependent manner. If the
changes were dose dependent and the differences were sta-
tistically significant from the control group values, then the
changes were considered statistically significant from a toxi-
cological point of view. The results of blood biochemistry pa-
rameters and morphology did not show any statistically
significant differences between the control and menaqui-
none-7-receiving groups. External examination of the control
and experimental animals, including examination of the
body, head, limbs, and discharges from natural orifices such
as mouth, nose, vagina, anus, and penis at autopsy did not
reveal any significant macroscopic changes in any tested
animals.
During the microscopic examination, no histopathological
lesions or changes were found in any of the organs studied,
except for the following changes in reproductive organs. The
only observation of note is the observation of features of
ovarian, uterus, and testicular stimulation at higher dose
levels (0.5 mg/kg and 1 mg/kg). In the ovaries, an increase in
size and number of mature follicles was observed in groups
receiving menaquinone-7 at concentrations of 0.5 mg/kg and
1 mg/kg. In the uterus, an increase in size of the muscular
layer and proliferation of the epithelial layer were observed in
groups receiving menaquinone-7 at concentrations of 0.5 mg/
kg and 1 mg/kg. In testis, the evidence of increased sper-
matogenesis was observed in groups receiving menaquinone-
7 at concentrations of 0.5 mg/kg and 1 mg/kg. These effects in
reproductive organs were not significant in groups receiving
menaquinone-7 at 0.1 mg/kg dose level.
The potential genotoxicity ofmenaquinone-7was assessed
by employing two assay systems, Ames and micronucleus
test. The results indicate that menaquinone-7 does not
have genotoxic and mutagenic potentials. Interestingly, astatistically significant increase in the proportion of poly-
chromatic cell population was observed in the menaquinone-
7 group (compared to the control group), which might have
contributed to increased hematopoietic activity of bone
marrow in the menaquinone-7 group. Typically, compounds
affecting bone marrow adversely, such as cytotoxic drugs,
decrease polychromatic cell population.
In conclusion, in this study, various toxicological evalua-
tions confirmed the safety of oral intake of menaquinone-7.
Acute and subacute toxicity studies demonstrated oral
administration of menaquinone-7 with no adverse effects in
both sex of animals. These results indicate thatmenaguinone-
7, in the MenaquinGold form, was very well tolerated by the
experimental animals, and did not show any preclinical or
clinical toxicity at the dose levels that are several times higher
than the average estimated dietary intake of menaquinone-7.Conflicts of interest
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